The inherited human disorders sialidosis and galactosialidosis are the result of deficiencies of glycoproteinspecific a-neuraminidase (acylneuraminyl hydrolase, EC 3.2.1.18; sialidase) activity. Two genes were determined to be necessary for expression of neuraminidase by using humanmouse somatic cell hybrids segregating human chromosomes.
human neuraminidase activity required both chromosomes 10 and 20 to be present. Analysis of human neuraminidase expression in interspecific hybrid cells or polykaryocytes formed from fusion of mouse RAG (hypoxanthine/guanine phosphoribosyltransferase deficient) or LM/TK-cell lines with human sialidosis or galactosialidosis fibroblasts indicated that the RAG cell line complemented the galactosialidosis defect, but the LM/TK-cell line did not. This eliminates the requirement for this gene in RAG-human hybrid cells and explains the different chromosome requirements of these two hybrid panels. Fusion of LM/TK-cell hybrids lacking chromosome 10 or 20 (phenotype 10+,20-and 10-,20+) and neuraminidase-deficient fibroblasts confirmed by complementation analysis that the sialidosis disorder results from a mutation on chromosome 10, presumably encoding the neuraminidase structural gene. Galactosialidosis is caused by a mutation in a second gene required for neuraminidase expression located on chromosome 20. Several inherited diseases have been found to be associated with a deficiency of glycoprotein-specific N-acetyl-aneuraminidase activity (acylneuraminyl hydrolase, EC 3.2.1.18; sialidase). These disorders are typically classified as the sialidoses, which have only a neuraminidase deficiency, and the galactosialidoses, which have a coexistent deficiency of P-galactosidase (1, 2) . The sialidosis disorder, originally termed lipomucopolysaccharidosis (3) , includes several variants with different degrees of clinical severity, including an adult-onset form known as sialidosis type I and the infantileonset variant known as mucolipidosis I or sialidosis type II (4, 5) . The galactosialidosis disorder, which has also been termed the Goldberg Syndrome (6), GM1 gangliosidosis type 4 (7), the cherry-red-spot-myoclonus syndrome with dementia (2) , and the juvenile-onset form of sialidosis type II (8) , is also clinically heterogeneous (9, 10) .
The primary defect in the sialidoses is thought to be a mutation in the neuraminidase structural gene. Obligate heterozygotes show a gene-dosage effect and have approximately half the normal neuraminidase levels (11, 12) . Obligate galactosialidosis heterozygotes have not consistently shown a reduction in either ,B-galactosidase or a-neuraminidase (2, 9, (13) (14) (15) (16) . Complementation studies from a number of laboratories show that the primary defect is different from that causing single deficiencies of P-galactosidase (GM1-gangliosidosis) or neuraminidase (7, (17) (18) (19) . The residual 3-galactosidase activity in galactosialidosis fibroblasts exists entirely as a monomer with an absence of a large multimer form found in normal cells (20) . The mutation causing galactosialidosis also causes a decrease in turnover time due to an increased susceptibility of,-galactosidase to proteolytic degradation (20, 21) . The P-galactosidase deficiency, but not the neuraminidase deficiency, can be corrected by the addition of protease inhibitors (21) (22) (23) (24) . This could be accomplished also with the addition of a "corrective factor" concentrated from cell culture medium, which has characteristics of a glycoprotein (23) (24) (25) . Recent evidence suggests that the mutation causing galactosialidosis results in an absence of a 32-kDa glycoprotein in anti-p-galactosidase immunoprecipitates, and this protein was postulated to be the primary defect in galactosialidosis (23) .
We present evidence for the chromosomal assignment of two genes required for the expression of human neuraminidase in somatic cell hybrids. In addition, our evidence indicates that the sialidosis and galactosialidosis diseases are caused by mutations in these genes located on chromosomes 10 and 20, respectively. A portion of this work has been presented in abstract form (26) .
MATERIALS AND METHODS
Fibroblasts and Hybrid Cells. The fibroblasts used were GM1718, derived from an infantile-onset variant of sialidosis type II (mucolipidosis I), and GM806, derived from a subject with an early-onset form of galactosialidosis. Hybrid cells were made by fusing normal human cells or cells with balanced chromosomal translocations with either mouse LM/TK-[thymidine kinase (TK) deficient] or mouse RAG (hypoxanthine/guanine phosphoribosyl transferase deficient) cells and selecting clones in hypoxanthine/aminopterin/thymidine selection medium as described (27) . The presence of human chromosomes was determined in each hybrid clone by scoring for previously mapped human enzyme markers and by karyotype analysis with trypsin/Giemsa banding (28) .
Neuraminidase Assays. Hybrids used for chromosomal localization studies were analyzed for human neuraminidase expression as freshly harvested cultures due to the lability of this enzyme to freezing. Hybrid harvests were scored for neuraminidase and analyzed karyotypically on the same passage. Hybrid cultures were rinsed in Dulbecco's phosphate-buffered saline and scraped from flasks with a rubber Abbreviation: TK, thymidine kinase.
The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. 10) , and the fluorescence was determined with an Aminco fluorimeter. The inclusion of bovine serum albumin at 1 mg/ml or 1 mM CaCl2 in assays or the preparation of homogenates in the presence of 1 mM phenylmethylsulfonyl fluoride had no effect on activity. Protein concentration was measured by using a modification of the Folin phenol procedure (30) .
Complementation Analysis. Each of the two cultures used in complementation experiments was seeded at half the confluent cell density, and the mixture was cultivated overnight. These cultures were fused by using 42% (wt/vol) polyethylene glycol 1000 (Koch-Light Laboratories) containing 7% (vol/vol) dimethyl sulfoxide (31) , and the resulting polykaryocytes were enriched by sedimentation velocity under sterile conditions with a Sta-Put apparatus (Johns Scientific, Toronto) as described (19) . This polykaryocyte fraction was cultured for 10-14 days, and the neuraminidase activity was determined along with cultures of each parental cell type and a cocultivated mixture. In complemnentation experiments involving human fibroblasts and RAG or LM/TK-cells, the polykaryocytes were cultivated in hypoxanthine/aminopterin/thymidine selection medium in order to inhibit growth of the unfused mouse parental cells. A significant increase in the neuraminidase activity of the polykaryocyte fraction over that of the cocultivated mixture and parental cell activity range, as determined with Student's t test (at the 1% confidence level), was assumed to indicate complementation.
RESULTS
Somatic Cell Hybrid Mapping of Neuraminidase. The presence of human neuraminidase activity in human-mouse somatic cell hybrids that segregate human chromosomes could be determined on the basis of a quantitative assay. Mouse RAG and LM/TK-parental cells, which were used to make somatic cell hybrids, had low levels of neuraminidase activity (<8% of that of normal human cells) under the assay conditions used (Table 1) . Therefore, the human activity in a hybrid cell could be quantitated by the amount of activity in excess of the mouse cell activity levels. Hybrid cells were found to have a large variation in neuraminidase activity because of the different numbers of the chromosome(s) encoding neuraminidase genes present in each hybrid ( (Table  1) . Hybrid clone XTR-3 BH contains del(10)(q23--qter) (deletion in chromosome 10 in region q23--qter).
mg for LM/TK-hybrids) were scored negative for human activity. Hybrid cells with neuraminidase activity well above this range (>20 nmol/hr per mg for human-RAG hybrids and >9 nmol/hr per mg for human-LM/TK-hybrids) were scored as positive (Table 2 ). Hybrid cells with activity levels between these upper and lower thresholds were not considered in discordance calculations. These hybrids were eliminated because of the variabilities associated with the nonquantitative scoring for human enzyme markers present at low levels in hybrid cells. The presence of human neuraminidase in hybrid cells was also confirmed qualitatively by mobility differences between human and mouse enzymes following cellulose acetate electrophoresis (unpublished data).
In each hybrid the human chromosome content was determined karyotypically and by scoring for the presence of previously mapped human enzyme markers. The correlation between the presence of human neuraminidase and each human chromosome is shown in Tables 2 and 3, expressed as the discordance frequency. Instances where chromosomes were present in <15% of the 30 metaphase spreads analyzed for each hybrid were not considered in calculating discordance percentages in Table 3 . The findings from a panel of 28 RAG-human hybrids indicated that the expression of neuraminidase was completely concordant only with chromosome 10 and the enzyme markers glutamic-oxaloacetic transaminase 1 (GOTI) and adenosine kinase (ADK), which had been mapped previously to chromosome 10 (32, 33) . For all other chromosomes, the expression of neuraminidase and the chromosome was discordant in four or more hybrids 1818 Genetics: Mueller et al. (Table 2 ) based on the activity thresholds as discussed in the text. (Table 3 ). This indicates that a gene necessary for neuraminidase expression is encoded on human chromosome 10. Further, the presence of neuraminidase activity in hybrid XTR-3-BsAg H with a deletion in chromosome 10 in the q23-*qter region indicated that this gene is located in the (pter-*q23) region of chromosome 10. A second hybrid panel consisting of 27 human-LM/TK-somatic cell hybrids indicated that human neuraminidase expression was apparently concordant with the presence of human chromosome 20 (Table 3) . For all other chromosomes, the discordance frequency was 21% or more, including six hybrids that demonstrated discordance with chromosome 10 (24% discordance, explained below). This suggests that another gene controlling the expression of neuraminidase is encoded on human chromosome 20.
Expression of Neuraminidase Deficiencies in Somatic Cell Hybrids. To explain this apparent discrepancy in the mapping results from these two hybrid panels, we constructed hybrid cells using sialidosis and galactosialidosis fibroblasts as the human parental cells and tested for human neuraminidase expression. Sialidosis and galactosialidosis fibroblasts are known to be caused by mutations in different genes, since neuraminidase is complemented in polykaryocytes formed from a sialidosis-galactosialidosis fibroblast fusion experiment (17) (18) (19) . Hybrid cells formed from fusion of mouse RAG with galactosialidosis fibroblasts (GAR hybrids) have significant levels of neuraminidase activity in those hybrids retaining chromosome 10 ( Table 4 ). The activity in each GAR hybrid varied somewhat according to the numbers of chromosome 10 present, but chromosome 20 was not necessary for expression. This indicates that the neuraminidase gene on chromosome 10 is functionally normal in this galactosialidosis subject and also that RAG cells have a gene or protein similar to that defective in this disorder. Therefore, in human-RAG hybrid cells made with normal human cells, human neuraminidase can be expressed in the absence of this gene, and mapping analysis detected only a single requirement for chromosome 10 (Table 3) .
Hybrid cells formed from the fusion of sialidosis fibroblasts-LM/TK-cells have no detectable human neuraminidase activity, whether human chromosomes 10, 20, or both 10 and 20 were present (Table 4) . Further, no increases in neuraminidase activity could be detected in enriched polykaryocytes formed from fusion of these cells (Table 5) . Hybrid cells from the fusion of LM/TK--galactosialidosis fibroblasts were not successfully constructed. However, complementation analysis using enriched polykaryocytes from fusion of LM/TK--galactosialidosis fibroblasts did not demonstrate any increases in neuraminidase activity ( Table  5 ), indicating that LM/TK-cells, unlike RAG cells, lack the gene or protein that complements the galactosialidosis defect. Since LM/TK-cells apparently complement neither the sialidosis nor the galactosialidosis mutations, there is a requirement for both of these genes before human neuraminidase can be expressed in LM/TK-hybrid cells constructed from normal human cells (Table 3 ). All LM/TK--human hybrid cells in Table 3 that are scored positive for neuraminidase have both chromosomes 10 and 20. All six hybrid clones in which the expression of neuraminidase and chromosome 10 was discordant contained chromosome 10 but had no detectable human neuraminidase activity. All of these hybrid clones lack human chromosome 20, explaining the absence of human neuraminidase activity.
Chromosomal Assignment of Sialidosis and Galactosialidosis Mutations. Complementation analysis also was used to determine whether either of the genes on chromosomes 10 and 20 was mutated in the sialidosis and galactosialidosis disorders. Two hybrid clones from the LM/TK--human hybrid panel were identified that have the chromosomal phenotypes 10+,20-and 10-,20+. These hybrids were used in comple- Genetics: MueUer et al. mentation experiments with sialidosis and galactosialidosis fibroblasts ( Table 5 ). The 10-,20+ hybrid has weak levels of human neuraminidase activity and was not included in the initial assignment studies (Tables 2 and 3 (Table 2) . Human chromosomes in hybrid cells are rarely present at their diploid number (60 homologues out of the 30 metaphase spreads that were analyzed), and hybrid cells with as few as 15% of possible homologues (9/60) were scored as positive. Therefore, the low levels of human neuraminidase activity in LM/TK-hybrid cells with both chromosomes scored positive reflect the low numbers of hybrid cells containing sufficient numbers of both chromosomes.
We also have shown that the deficiency of neuraminidase activity in two subjects with sialidosis and galactosialidosis is associated with a loss in function of the genes on chromosomes 10 and 20, respectively. It has not been determined whether this can be generalized for all subjects with these diseases, although no genetic heterogeneity has thus far been identified within sialidosis or galactosialidosis (17, 19) . The indirect evidence from the literature (i.e., a gene-dosage effect in obligate heterozygotes and kinetic alterations in the enzyme of homozygotes) suggests that the sialidosis disorder is caused by a mutation in the neuraminidase structural gene. We presume, therefore, that the gene on chromosome 10 encodes the structural enzyme protein. Oohira et al. (34) reported that there was a suggestion of linkage between a locus causing a case of sialidosis II (single neuraminidase deficiency) with the HLA complex located on chromosome 6. Their analysis, however, was based on only seven informative family members, and this may not be sufficient data to establish linkage.
Our data also indicate that the galactosialidosis disorder is caused by a loss in function of the gene located on chromosome 20. Evidence from complementation analysis and from 1820 Genetics: MueUer et al.
